Looking back from 2024 to 2025, the in vitro diagnostic reagent (IVD) industry was once shrouded in layers of clouds. The growth rate of revenue slowed down and the net profit cut sharply. The once rapid growth came to an abrupt end, and the industry entered a cruel stage of de foam. Many people see this period as a cold winter for the industry, but looking back at it from the spring of March 2026, this reshuffle is not the end of the industry, but an evolutionary choice to eliminate impatience and screen high-quality enterprises. The IVD industry, which has survived the painful period, has long abandoned the old model of extensive expansion and completed transformation in three directions: overseas layout, deep operation, and financial control. It has embarked on a more stable development path and also pointed out the direction for upstream and downstream enterprises in the industry chain.

enzyme preparations

1、 New situation of going global: from product export to localization and deep cultivation at home

Previously, most domestic IVD companies went abroad in a shallow mode of simply exporting products, relying on low prices to increase volume, lacking localized layout, and having extremely weak risk resistance capabilities. After experiencing industry reshuffling, leading companies have adjusted their overseas strategies, bidding farewell to a single export model and turning to localized home operations. Nowadays, IVD going global is no longer just about selling products overseas, but about building localized teams in key markets, completing localized registration and certification, laying out warehousing and after-sales systems, and deeply adapting to local market policies, needs, and usage habits. This model can not only avoid trade barriers and price wars, but also enhance brand discourse power, allowing domestic IVDs to truly transform from "going out" to "going in", establish a foothold in the global market, and become the core growth pole for industry breakthroughs.

2、 Operational iteration: from extensive expansion to intelligent and refined farming

During the industry dividend period, many IVD companies pursue extensive expansion, blindly laying out channels and expanding categories, emphasizing scale over quality. Although the market coverage seems extensive, the operational efficiency is actually low. After the de foam, the industry completely said goodbye to this inefficient model and turned to digital, intelligent and deep cultivation. Enterprises are starting to focus on the core advantage track, using digital tools to accurately connect with terminal needs, optimize product research and development and production processes, and rely on intelligent means to improve supply chain efficiency and reduce operating costs. At the same time, enterprises pay more attention to product quality and clinical value, abandon homogeneous low-end competition, focus on core raw materials and other bottleneck areas, and seize market share with technological strength.

3、 Financial Reshaping: Cash Flow as the Core, Building a Solid Bottom Line for Survival and Development

After experiencing the dilemma of tight funding chain, the IVD industry has completely restructured its financial logic, replacing scale and gross profit with cash flow, becoming the top priority for the survival and development of enterprises. Previously, some companies blindly expanded, invested heavily in assets, and accumulated accounts receivable, leading to cash flow disruptions and ultimately being eliminated by the market. Nowadays, companies in the industry are generally tightening their belts, strictly controlling cost expenditures, optimizing payment cycles, reducing unnecessary investments, and prioritizing the stability of cash flow. At the same time, enterprises pay more attention to supply chain security, choose stable and reliable upstream partners, shorten accounting periods, reduce inventory backlog, and build a healthy financial model with light assets and high turnover. Only by holding the bottom line of cash flow can enterprises withstand market fluctuations and establish a long-term foothold in industry competition.

After two years of shuffling and settling, the IVD industry has completed self innovation and ushered in a new stage of high-quality development after the foam has faded. The steady progress of the industry cannot be separated from the support of upstream core raw material enterprises. As a company that has been deeply involved in the field of biochemical raw materials for nearly 20 years, Hubei Xindesheng has always kept up with industry trends, focusing on core IVD raw materials such as biological buffering agents, color reagents, chemiluminescence reagents, enzyme preparations, etc. With stable quality, sufficient production capacity, and fast delivery capabilities, it helps downstream enterprises strictly control costs, ensure supply chain security, and hold the bottom line of cash flow. Coincidentally with the opening of the 2026 Xiamen CACLP exhibition, Xindesheng is waiting for industry colleagues at booth 4-A3012 in Hall 4 to discuss ways to break through the industry and work together with high-quality domestic raw materials to help the IVD industry achieve stability and success.